Literature DB >> 10768706

Mechanisms of the salutary effects of dehydroepiandrosterone after trauma-hemorrhage: direct or indirect effects on cardiac and hepatocellular functions?

D Jarrar1, P Wang, W G Cioffi, K I Bland, I H Chaudry.   

Abstract

BACKGROUND: Dehydroepiandrosterone (DHEA) is the most abundant adrenal hormone in man and has been shown to improve immune functions after trauma-hemorrhage. However, it remains unknown whether this agent has any salutary effects on the depressed organ functions under such conditions. HYPOTHESIS: Administration of DHEA after trauma-hemorrhage attenuates depressed cardiac and hepatocellular functions, and beneficial effects are mediated via the estrogen receptors. DESIGN, INTERVENTIONS, AND MAIN OUTCOME MEASURES: Male rats underwent laparotomy and were then bled to and maintained at a mean arterial pressure of 40 mm Hg until 40% of the maximal bleed-out volume was returned in the form of Ringer lactate (RL) solution. The animals were then resuscitated with 4 times the maximum bleed-out volume with RL for 60 minutes. Subcutaneous administration of DHEA (30 mg/kg of body weight) or vehicle occurred after resuscitation. At 24 hours after resuscitation, cardiac output was measured by a dye-dilution technique. Hepatocellular function, ie, the maximum velocity of indocyanine green clearance (Vmax) and the efficiency of the active transport (Km), was determined using an in vivo hemoreflectometer. Plasma levels of DHEA, sex hormone binding globulin, 17beta-estradiol, and testosterone were also determined. Moreover, additional groups of animals received a high-affinity estrogen receptor antagonist (ICI 182,780) with or without DHEA treatment.
RESULTS: Cardiac output decreased by 12.9% at 24 hours after trauma-hemorrhage; however, it was similar to shams in DHEA-treated animals. Moreover, hepatocellular function was significantly depressed after hemorrhage (Vmax, -74.4%; Km, -62.3%), whereas DHEA treatment restored those values to sham levels. Plasma levels of 17beta-estradiol and testosterone were not significantly altered in animals receiving DHEA. The hemorrhage group treated with DHEA and ICI 182,780 showed markedly depressed cardiac and hepatocellular functions.
CONCLUSIONS: Since DHEA treatment after trauma-hemorrhage restored the depressed cardiac and hepatocellular functions, it appears that DHEA is a safe and inexpensive adjunct to fluid resuscitation for restoring the depressed cardiac and hepatocellular responses after severe hemorrhagic shock in male subjects. Furthermore, since ICI 182,780 administration with DHEA abolished the salutary effects of DHEA, it appears that these effects on cardiac and hepatocellular functions after trauma-hemorrhage are mediated via the estrogen receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768706     DOI: 10.1001/archsurg.135.4.416

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Dehydroepiandrosterone protects against hepatic glycolipid metabolic disorder and insulin resistance induced by high fat via activation of AMPK-PGC-1α-NRF-1 and IRS1-AKT-GLUT2 signaling pathways.

Authors:  Longlong Li; Yao Yao; Jinlong Zhao; Ji Cao; Haitian Ma
Journal:  Int J Obes (Lond)       Date:  2020-01-07       Impact factor: 5.095

2.  Hormonally active women tolerate shock-trauma better than do men: a prospective study of over 4000 trauma patients.

Authors:  Edwin A Deitch; David H Livingston; Robert F Lavery; Sean F Monaghan; Advaith Bongu; George W Machiedo
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

3.  Dehydroepiandrosterone: a modulator of cellular immunity and heat shock protein 70 production during polymicrobial sepsis.

Authors:  Reiner Oberbeck; Hanno Deckert; Jörg Bangen; Phillip Kobbe; Daniel Schmitz
Journal:  Intensive Care Med       Date:  2007-09-26       Impact factor: 17.440

4.  Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats.

Authors:  Rui-Sheng Duan; Hans Link; Bao-Guo Xiao
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.